Literature DB >> 26575974

The quest for spatio-temporal control of CAR T cells.

Jie Sun1,2, Michel Sadelain1,2.   

Abstract

Chimeric antigen receptors (CARs) are synthetic receptors capable of directing potent antigen-specific anti-tumor T cell responses. A recent report by Wu et al. extends a series of strategies aiming to curb excessive T cell activity, utilizing in this instance a chemical dimerizer to aggregate antigen-binding, T cell-activating and costimulatory domains.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26575974      PMCID: PMC4670991          DOI: 10.1038/cr.2015.131

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  9 in total

1.  PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.

Authors:  Victor D Fedorov; Maria Themeli; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-12-11       Impact factor: 17.956

2.  Controlling signal transduction with synthetic ligands.

Authors:  D M Spencer; T J Wandless; S L Schreiber; G R Crabtree
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

Review 3.  Designing chimeric antigen receptors to effectively and safely target tumors.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2015-01-23       Impact factor: 7.486

4.  Redirection of genetically engineered CAR-T cells using bifunctional small molecules.

Authors:  Min Soo Kim; Jennifer S Y Ma; Hwayoung Yun; Yu Cao; Ji Young Kim; Victor Chi; Danling Wang; Ashley Woods; Lance Sherwood; Dawna Caballero; Jose Gonzalez; Peter G Schultz; Travis S Young; Chan Hyuk Kim
Journal:  J Am Chem Soc       Date:  2015-02-24       Impact factor: 15.419

Review 5.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

6.  T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing.

Authors:  Ko Kudo; Chihaya Imai; Paolo Lorenzini; Takahiro Kamiya; Koji Kono; Andrew M Davidoff; Wee Joo Chng; Dario Campana
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

7.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

8.  Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

Authors:  Chia-Yung Wu; Kole T Roybal; Elias M Puchner; James Onuffer; Wendell A Lim
Journal:  Science       Date:  2015-09-24       Impact factor: 47.728

9.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.

Authors:  Christopher C Kloss; Maud Condomines; Marc Cartellieri; Michael Bachmann; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2012-12-16       Impact factor: 54.908

  9 in total
  9 in total

1.  Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer.

Authors:  Feifei Luo; Jiawen Qian; Jiao Yang; Yuting Deng; Xiujuan Zheng; Jie Liu; Yiwei Chu
Journal:  Cell Res       Date:  2016-06-24       Impact factor: 25.617

2.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

Review 3.  Therapeutic T cell engineering.

Authors:  Michel Sadelain; Isabelle Rivière; Stanley Riddell
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

4.  Chemically inducible split protein regulators for mammalian cells.

Authors:  Erik Rihtar; Tina Lebar; Duško Lainšček; Katarina Kores; Samo Lešnik; Urban Bren; Roman Jerala
Journal:  Nat Chem Biol       Date:  2022-09-26       Impact factor: 16.174

Review 5.  Chimeric antigen receptors: driving immunology towards synthetic biology.

Authors:  Michel Sadelain
Journal:  Curr Opin Immunol       Date:  2016-06-30       Impact factor: 7.486

6.  Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

Authors:  Esther Drent; Renée Poels; Manon J Mulders; Niels W C J van de Donk; Maria Themeli; Henk M Lokhorst; Tuna Mutis
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

7.  Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches.

Authors:  MyLinh T Duong; Matthew R Collinson-Pautz; Eva Morschl; An Lu; Slawomir P Szymanski; Ming Zhang; Mary E Brandt; Wei-Chun Chang; Kelly L Sharp; Steven M Toler; Kevin M Slawin; Aaron E Foster; David M Spencer; J Henri Bayle
Journal:  Mol Ther Oncolytics       Date:  2018-12-20       Impact factor: 7.200

8.  A conformation-specific ON-switch for controlling CAR T cells with an orally available drug.

Authors:  Charlotte U Zajc; Markus Dobersberger; Irene Schaffner; Georg Mlynek; Dominic Pühringer; Benjamin Salzer; Kristina Djinović-Carugo; Peter Steinberger; Annika De Sousa Linhares; Nicole J Yang; Christian Obinger; Wolfgang Holter; Michael W Traxlmayr; Manfred Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-17       Impact factor: 12.779

Review 9.  Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.

Authors:  Yixin Zou; Wei Xu; Jianyong Li
Journal:  J Hematol Oncol       Date:  2018-11-20       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.